EXPANDING THERAPEUTIC HORIZONS OF GLP-1 RECEPTOR AGONISTS: FROM METABOLIC REGULATION TO NEUROPROTECTION IN ALZHEIMER’S DISEASE AND ADDICTION DISORDERS – A COMPREHENSIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6289Keywords:
GLP-1 Receptor Agonists, Alzheimer’s Disease, Substance Use Disorder, Alcohol Use Disorder, Drug RepurposingAbstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed and approved for the treatment of type 2 diabetes and obesity, are now demonstrating unprecedented therapeutic potential that extends beyond metabolic regulation alone. This review article aims to provide a comprehensive summary and analysis of the current state of knowledge regarding the expanding clinical horizons of GLP-1RAs, with a particular focus on their neuroprotective properties in Alzheimer’s disease (AD) and their use in the treatment of substance use disorders (SUDs), including alcohol dependence. Based on a systematic review of selected literature, including the latest preclinical studies and clinical trials, the multifaceted mechanisms of GLP-1 action in the central nervous system were analyzed. The accumulated evidence indicates that GLP-1 receptor agonists (GLP-1RAs) effectively cross the blood-brain barrier, alleviate systemic and local neuroinflammation, reduce oxidative stress, and improve synaptic plasticity. These effects translate into a halt in neuronal degeneration and beneficial cognitive outcomes in patients with early symptoms of AD. Furthermore, these drugs have been shown to innovatively modulate reward pathways in the brain (including the dopaminergic system), effectively reducing drug cravings, compulsive behaviors, and the consumption of alcohol and other addictive substances. In summary, the repurposing of GLP-1 receptor agonists represents an extremely promising strategy for treating complex neurological and psychiatric disorders. However, further large-scale clinical trials are necessary to optimize dosing protocols and confirm the long-term safety profile.
References
Martinelli, S., Mazzotta, A., Longaroni, M., & Petrucciani, N. (2024). Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials. Drug and Alcohol Dependence, 264, Article 112424. https://doi.org/10.1016/j.drugalcdep.2024.112424
Klausen, M. K., Knudsen, G. M., Vilsbøll, T., & Fink-Jensen, A. (2025). Effects of GLP-1 receptor agonists in alcohol use disorder. Basic & Clinical Pharmacology & Toxicology, 136, Article 270004. https://doi.org/10.1111/bcpt.70004
Klausen, M. K., Thomsen, M., Wörtwein, G., & Fink-Jensen, A. (2022). The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. British Journal of Pharmacology, 179(4), 625–641. https://doi.org/10.1111/bph.15677
Jerlhag, E. (2025). GLP-1 receptor agonists: Promising therapeutic targets for alcohol use disorder. Endocrinology, 166(4), Article bqaf028. https://doi.org/10.1210/endocr/bqaf028
Völker, K. M., Prechtl, B. L. H., Bormann, N. L., & Choi, D. S. (2025). The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review. Frontiers in Pharmacology, 16, Article 1702448. https://doi.org/10.3389/fphar.2025.1702448
Alves, G. A. M., Teranishi, M., Ortega, A. C. T. C. G., James, F., & Arachchige, A. S. P. M. (2025). Mechanisms of GLP-1 in modulating craving and addiction: Neurobiological and translational insights. Medical Sciences, 13(3), Article 136. https://doi.org/10.3390/medsci13030136
Guo, J., Hayes, M. R., Leggio, L., Oru, E., & Rinaman, L. (2025). GLP-1 receptor agonists and research to treat overeating and substance use disorders. The Journal of Neuroscience, 45(46). https://doi.org/10.1523/JNEUROSCI.1375-25.2025
Hölscher, C. (2024). Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making? Neuropharmacology, 253, Article 109952. https://doi.org/10.1016/j.neuropharm.2024.109952
Monney, M., Jornayvaz, F. R., & Gariani, K. (2023). GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes & Metabolism, 49, Article 101470. https://doi.org/10.1016/j.diabet.2023.101470
Yildirim Simsir, I., Erdem Soyaltin, U., & Cetinkalp, S. (2018). Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 12(4), 469–475. https://doi.org/10.1016/j.dsx.2018.03.002
Liang, Y., Doré, V., Rowe, C. C., & Krishnadas, N. (2024). Clinical evidence for GLP-1 receptor agonists in Alzheimer's disease: A systematic review. Journal of Alzheimer's Disease Reports, 8(1), 777–789. https://doi.org/10.3233/ADR-230181
Reich, N., & Hölscher, C. (2022). The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review. Frontiers in Neuroscience, 16, Article 970925. https://doi.org/10.3389/fnins.2022.970925
Erbil, D., Eren, C. Y., Demirel, C., Küçüker, M. U., Solaroğlu, I., & Yapıcı Eser, H. (2019). GLP-1's role in neuroprotection: A systematic review. Brain Injury, 33(6), 734–819. https://doi.org/10.1080/02699052.2019.1587000
Talbot, K. (2014). Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. Neurodegenerative Disease Management, 4(1), 31–40. https://doi.org/10.2217/nmt.13.73
Hui, E. K., Mukadam, N., Kohl, G., & Livingston, G. (2025). Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: A systematic review and meta-analysis. Journal of Alzheimer's Disease, 104(3), 627–648. https://doi.org/10.3233/JAD-240728
Zhang, P., Mao, C., Sun, A., Yang, Y., Hou, Y., Fu, Z., Babak, T., Leverenz, J. B., Pieper, A. A., Luo, Y., Cummings, J., & Cheng, F. (2025). Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease. Alzheimer's & Dementia, 21, Article e70639. https://doi.org/10.1002/alz.70639
Edison, P., Femminella, G. D., Ritchie, C., Nowell, J., Holmes, C., Walker, Z., Ridha, B., Raza, S., Livingston, N. R., Frangou, E., Love, S., Williams, G., Lawrence, R., Mcfarlane, B., Archer, H., Coulthard, E., Underwood, B. R., Koranteng, P., Karim, S., … Ballard, C. (2026). Liraglutide in mild to moderate Alzheimer's disease: A phase 2b clinical trial. Nature Medicine, 32, 353–361. https://doi.org/10.1038/s41591-025-04106-7
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025). GLP-1 and the degenerating brain: Exploring mechanistic insights and therapeutic potential. International Journal of Molecular Sciences, 26(21), Article 10743. https://doi.org/10.3390/ijms262110743
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025). The expanding role of GLP-1 receptor agonists: A narrative review of current evidence and future directions. eClinicalMedicine, 86, Article 103363. https://doi.org/10.1016/j.eclinm.2025.103363
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024). Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9, Article 234. https://doi.org/10.1038/s41392-024-01931-z
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022). Anti-inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases. International Journal of Molecular Sciences, 23(17), Article 9583. https://doi.org/10.3390/ijms23179583
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023). Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease. Ageing Research Reviews, 89, Article 101979. https://doi.org/10.1016/j.arr.2023.101979
O'Farrell, M., Almohaileb, F. I., & le Roux, C. W. (2025). Glucagon-like peptide-1 analogues reduce alcohol intake. Diabetes, Obesity and Metabolism, 27(3), 1601–1604. https://doi.org/10.1111/dom.16152
Subhani, M., Dhanda, A., King, J. A., Warren, F. C., Creanor, S., Davies, M. J., Eldeghaidy, S., Bawden, S., Gowland, P. A., Bataller, R., Greenwood, J., Kaar, S., Bhala, N., & Aithal, G. P. (2024). Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: A systematic review. eClinicalMedicine, 78, Article 102920. https://doi.org/10.1016/j.eclinm.2024.102920
Sudhinaraset, M., Wigglesworth, C., & Takeuchi, D. T. (2016). Social and cultural contexts of alcohol use: Influences in a social-ecological framework. Alcohol Research: Current Reviews, 38(1), 35–45.
Jerlhag, E. (2018). GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence. Neuropharmacology, 136, 343–349. https://doi.org/10.1016/j.neuropharm.2018.01.013
Gandhi, A., & Parhizgar, A. (2025). GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: Endocrine pathways, clinical evidence, and future directions. Frontiers in Endocrinology, 16, Article 1708565. https://doi.org/10.3389/fendo.2025.1708565
Du, H., Meng, X., Yao, Y., & Xu, J. (2022). The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease. Frontiers in Endocrinology, 13, Article 1033479. https://doi.org/10.3389/fendo.2022.1033479
Hong, C.-T., Chen, J.-H., & Hu, C.-J. (2024). Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease. Journal of Biomedical Science, 31, Article 102. https://doi.org/10.1186/s12929-024-01090-x
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., & Leggio, L. (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 8(12), Article e170671. https://doi.org/10.1172/jci.insight.170671
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Karolina Reczka, Zuzanna Zalewska , Julia Szymkowiak , Maria Woźniak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
